Management of gout

References

• Bellamy N., Downie W. W., Buchanan W. W. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of nonsteroidal anti‐inflammatory drugs. Br J Clin Pharmacol 1987; 24: 33–6
   PubMedGoogle Scholar
• Schlesinger N. Management of acute and chronic gouty arthritis: present state‐of‐the‐art. Drugs 2004; 64: 2399–416
   PubMed Web of Science ®Google Scholar
• Schlesinger N., Baker D. G., Schumacher H. R, Jr. Gout: how well have diagnostic tests and therapies been evaluated?. Cur Opin Orthop 2000; 11: 71–6
   Google Scholar
• Schlesinger N., Baker D. G., Schumacher H. R Jr. Gout: can management be improved?. Curr Opin Rheumatol 2001; 13: 240–4
   PubMed Web of Science ®Google Scholar
• Wallace S. L., Robinson H., Masi A. T., Decker J. L., McCarty D. J., Yu T. F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900
   PubMed Web of Science ®Google Scholar
• Agudelo C. A., Schumacher H. R Jr., Phelps P. Effect of exercise on urate crystal‐induced inflammation in canine joints. Arthritis Rheum 1972; 15: 609–16
   PubMed Web of Science ®Google Scholar
• Schumacher H. R Jr. Crystal induced arthritis: an overview. Am J Med 1996; 100((Suppl 2A))46–52
   PubMedGoogle Scholar
• Schlesinger N., Baker D. G., Beutler A. M., Hoffman B. I., Schumacher H. R Jr. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331–4
   PubMed Web of Science ®Google Scholar
• Dorwart B. B., Hansell J. R., Schumacher H. R Jr. Effects of cold and heat on urate‐induced synovitis in dog. Arthritis Rheum 1974; 17: 563–71
   PubMedGoogle Scholar
• Weede R. P. Poison in the pot: the legacy of lead. Southern Illinois University Press, Carbondale and Edwardsville 1984; 83
   Google Scholar
• Basic and clinical pharmacology, B. G Katzung. Appleton and Lange, Norwalk 1995; 536–9
   Google Scholar
• Levy M., Spino M., Read S. E. Colchicine: a state‐of‐the‐art review. Pharmacotherapy 1991; 11: 196–211
   PubMed Web of Science ®Google Scholar
• Schlesinger N., Schumacher H. R Jr., Catton M., Maxwell L. Colchicine therapy for acute gout. Cochrane Database Syst Rev 2006; (4): CD006190
   Google Scholar
• Ahern M. J., Reid C., Gordon T. P. Does colchicine work? Results of the first controlled study in gout. Austr N Z J Med 1987; 17: 301–4
   PubMedGoogle Scholar
• Paulus H. E., Schlosstein L. H., Godfrey R. C., Klinenberg J. R., Bluestone R. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1987; 17: 609–14
   Web of Science ®Google Scholar
• British Medical Association Royal Pharmaceutical Society of Great Britain. British national formulary. BMA, RPS, London 2002; 500 (No. 44)
   Google Scholar
• Morris I., Varughese G., Mattingly P. Colchicine in acute gout. Br Med J 2003; 327: 1275–6
   PubMed Web of Science ®Google Scholar
• Evans I. T., Wheeler M. T., Small R. E., Breitbach S. A., Sanders K. M., Roberts W. N. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143–8
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Saf 2007; 6: 625–9
   PubMed Web of Science ®Google Scholar
• Laine L. Nonsteroidal anti‐inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6: 489–504
   PubMedGoogle Scholar
• Allison M. C., Howatson A. G., Torrance C. J., Lee F. D., Russell R. I. Gastrointestinal damage associated with the use of nonsteroidal anti‐inflammatory drugs. N Engl J Med 1992; 327: 749–54
   PubMed Web of Science ®Google Scholar
• Sandler D. P., Burr F. R., Weinberg C. R. Nonsteroidal anti‐inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165–72
   PubMed Web of Science ®Google Scholar
• Kelly W., Wortmann R. L. Textbook of rheumatology, 4th edn, W. N Kelly. Saunders, Philadelphia 1993; 1340–51
   Google Scholar
• Emmerson B. T. The management of gout. N Engl J Med 1996; 334: 445–51
   PubMed Web of Science ®Google Scholar
• Smythe C. J., Percy J. S. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973; 32: 351–3
   PubMedGoogle Scholar
• Rousti A., Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative double‐blind trial. Scand J Rheumatol Suppl 1978; 21: 15–17
   Google Scholar
• Altman R. D., Honig S., Levin J. M., Lightfoot R. W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double‐blind comparative study. J Rheumatol 1988; 15: 1422–6
   PubMed Web of Science ®Google Scholar
• Weiner G. I., White S. R., Weitzner R. I., Rubenstein H. M. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; 22: 425–6
   PubMedGoogle Scholar
• Shrestha M., Morgan D. L., Moreden J. M., Singh R., Nelson M., Hayes J. E. Randomized double‐blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682–6
   PubMed Web of Science ®Google Scholar
• Macagno A., Di Giorgio E., Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423–9
   PubMedGoogle Scholar
• Schumacher H. R., Boice J., Dahikh D. I., Mulkopadhyay S., Malmstrom K., Ng J., et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002; 324: 1488–92
   PubMed Web of Science ®Google Scholar
• Rubin B. R., Burton R., Navarra S., Antigua J., Londono J., Pryhuber K. G., et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598–606
   PubMed Web of Science ®Google Scholar
• Willburger R. E., Mysler E., Derbot J., Jung T., Thurston H., Kreiss A., et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007; 46: 1126–32
   PubMed Web of Science ®Google Scholar
• Gordon G. V., Schumacher H. R. Management of gout. Am Fam Physician 1969; 10: 62–6
   Google Scholar
• Gray R. G., Tenenbaum J., Gottlieb N. L. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979; 10: 231–54
   Google Scholar
• Fernandez C., Noguera R., Gonzalez J. A., Pasquel E. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285–6
   PubMed Web of Science ®Google Scholar
• Groff G. D., Franck W. A., Raddatz D. A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329–36
   PubMed Web of Science ®Google Scholar
• Alloway J. A., Moriarty M. J., Hoogland Y. T., Nashel D. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111–13
   PubMed Web of Science ®Google Scholar
• Gutman A. B., Yu T. F. Effects of ACTH in gout. Am J Med 1950; 9: 24–6
   PubMedGoogle Scholar
• Wolfson W. Q., Cohn C., Levine R. Rapid treatment of acute gouty arthritis by concurrent administration of pituitary adrenocorticotropic hormone (ACTH) and colchicine. J Lab Clin Med 1949; 34: 1766–8
   Google Scholar
• Hollander J. L., Brown E. M., Elkinton J. R. Proceedings of the second clinical ACTH conference, vol. 2, J Mote. Blakston, Philadelphia 1951; 122–5
   Google Scholar
• Getting S. J., Christian H. C., Flower R. J., Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46: 2765–75
   PubMed Web of Science ®Google Scholar
• Getting S. J., Lam C. W., Chen A. S., Grieco P., Perretti M. Melanocortin 3 receptors control crystal‐induced inflammation. FASEB J 2006; 20: 2234–41
   PubMed Web of Science ®Google Scholar
• Getting S. J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006; 111: 1–15
   PubMedGoogle Scholar
• Ritter J., Kerr L. D., Valeriano‐Marcet J., Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696–9
   PubMed Web of Science ®Google Scholar
• Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803–5
   PubMed Web of Science ®Google Scholar
• Seigel L. B., Alloway J. A., Nashel D. J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994; 21: 1325–7
   PubMedGoogle Scholar
• Taylor C. T., Brooks N. C., Kelley K. W. Corticotropin for acute management of gout. Ann Pharmacother 2006; 35: 365–8
   Google Scholar
• Schlesinger N., Moore D. F., Sun J. D., Schumacher H. R. A survey of current evaluation and treatment of gout. J Rheumatol 2006; 33: 2050–2
   PubMed Web of Science ®Google Scholar
• Petersel D., Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007; 34: 1566–8
   PubMed Web of Science ®Google Scholar
• Rozenberg S., Lang T., Laatar A., Koeger A. C., Orcel P., Bourgerois P. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996; 63: 255–61
   PubMedGoogle Scholar
• Bellamy N., Gilbert J. R., Brooks P. M., Emmerson B. T., Campbell J. A survey of current prescribing practices of anti‐inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988; 15: 1841–71
   PubMed Web of Science ®Google Scholar
• Bellamy N., Brooks P. M., Gilbert R. J., Campbell J., McCredie M. A. Survey of current prescribing practices of anti‐inflammatory and urate lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989; 151: 537–51
   Google Scholar
• Stuart R. A., Gow P. J., Bellamy N., Campbell J., Grigor R. A survey of current prescribing practices of anti‐inflammatory and urate‐lowering drugs in gouty arthritis. N Z Med J 1991; 104: 115–17
   PubMedGoogle Scholar
• Dalbeth N., Haskard D. O. Mechanisms of inflammation in gout. Rheumatology 2005; 44: 1090–6
   PubMed Web of Science ®Google Scholar
• Zhang W., Doherty M., Bardin T., Barskova V., Conagham P., Gerster J., et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312–24
   PubMed Web of Science ®Google Scholar
• Jordan K. M., Cameron J. S., Snaith M., Zhang W., Doherty M., Seckl J., et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372–4
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum 2007; 57: 1324–8
   PubMed Web of Science ®Google Scholar
• Yu T. F., Gutman A. B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961; 55: 179–92
   PubMed Web of Science ®Google Scholar
• Paulus H. E., Schlosstein S. H., Godfrey R. G., Klinenberg J. R., Bluestone R. Prophylactic colchicine therapy of intercritical gout: a placebo‐controlled study of probenecid‐treated patients. Arthritis Rheum 1974; 17: 609–14
   PubMed Web of Science ®Google Scholar
• Borstad C. G., Bryant L. R., Abel M. P., Scroggie D. A., Harris M. D., Alloway J. A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gout arthritis. J Rheumatol 2004; 31: 2429–32
   PubMed Web of Science ®Google Scholar
• Wallace S. L., Singer J. Z., Duncan G. J., Wigley F. M., Kuncl R. W. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991; 18: 264–9
   PubMed Web of Science ®Google Scholar
• Kuncl R. W., Duncan G., Watson D., Alderson K., Rogawsky M. A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 3126: 1562–8
   Google Scholar
• Perez‐Ruiz F., Gonzalez Mielgo F. J., Herrero‐Beites A. Optimisation of the treatment of acute gout. Biodrugs 2000; 13: 45–53
   Google Scholar
• Simkin P. A., Gardner G. C. Colchicine use in cyclosporine treated transplant recipients: how little is too much?. J Rheumatol 2000; 27: 1334–7
   PubMedGoogle Scholar
• Becker M. A., Schumacher H. R Jr., Wortmann R. L., MacDonald P. A., Eustace D., Palo W. A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61
   PubMed Web of Science ®Google Scholar
• Simkin P. A. Management of gout. Ann Intern Med 1979; 90: 812–16
   PubMed Web of Science ®Google Scholar
• Schumacher H. R Jr. Crystal‐induced arthritis: an overview. Am J Med 1996; 100: 46–52
   PubMed Web of Science ®Google Scholar
• Schumacher H. R Jr., Edwards L. N., Perez‐Ruiz F., Becker M., Chen L. X., Furst D. E., et al. Outcome measures for acute and chronic gout. J Rheumatol 2005; 32: 2452–5
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Calabozo M., Fernandez‐Lopez M. J., Herrero‐Beites A. M., Ruiz‐Lucea E., Garcia‐Erauskin G., et al. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. J Clin Rheumatol 1999; 5: 49–55
   PubMed Web of Science ®Google Scholar
• McCarthy G., Barthelemy C. R., Veum J. A., Wortmann R. L. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991; 34: 1489–94
   PubMed Web of Science ®Google Scholar
• Pascual E. Persistence of monosodium urate crystals and low‐grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991; 34: 141–5
   PubMed Web of Science ®Google Scholar
• Pascual E., Batlle‐Gualda E., Martinez A., Rosas J., Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999; 131: 756–9
   PubMed Web of Science ®Google Scholar
• Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056–8
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Calabozo M., Pijoan J. I., Herrero‐Beites A. M., Ruibal A. Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356–60
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Martin I., Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007; 34: 1888–93
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Calabozo M., Herrero‐Beites A. M., Garcia‐Erauskin G., Pijoan J. I. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000; 86: 287–91
   PubMed Web of Science ®Google Scholar
• Choi H. K. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol 2005; 17: 141–6
   PubMed Web of Science ®Google Scholar
• Choi H. K., Curham C. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004; 51: 1023–9
   PubMed Web of Science ®Google Scholar
• Choi H. K., Curhan G. Alcohol and gout. Am J Med 2007; 120: e5
   PubMedGoogle Scholar
• Choi H. K., Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005; 17: 341–5
   PubMed Web of Science ®Google Scholar
• Choi H. K., Liu S., Curhan G. Intake of purine‐rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52: 283–9
   PubMed Web of Science ®Google Scholar
• Choi H. K., Atkinson K., Karlson E. W., Willett W., Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277–81
   PubMed Web of Science ®Google Scholar
• Wurzner G. C., Gersterb J. C., Chiolero A., Maillard M., Fallab‐Stubi C. L., et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1860
   Google Scholar
• Perez‐Ruiz F., Naredo E. Imaging modalities and monitoring measures of gout. Curr Opin Rheumatol 2007; 19: 128–33
   PubMed Web of Science ®Google Scholar
• Bosi‐Ferraz M., O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908–14
   PubMedGoogle Scholar
• Yamanaka H., Togashi R., Hakoda M., Terai C., Kashiwazaki S., Dan T., et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti‐hyperuricemic therapy. Adv Exp Med Biol 1998; 431: 13–18
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Hernando I., Villar I., Nolla J. M. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. Another insight to allopurinol‐related toxicity. J Clin Rheumatol 2005; 11: 129–33
   PubMedGoogle Scholar
• Bostom A. G., Kronenberg F., Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140–4
   PubMed Web of Science ®Google Scholar
• Raebel M. A., McClure D. L., Simon S. R., Chan K. A., Feldstein A. C., Gunter M. J., et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006; 40: 386–91
   PubMedGoogle Scholar
• Yu T. F., Gutman A. B. Effect of allopurinol on serum and urinary uric acid in primary and secondary gout. Am J Med 1964; 37: 885–98
   PubMed Web of Science ®Google Scholar
• Emmerson B. T., Gordon R. B., Cross M., Thompson D. B. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol 1987; 26: 445–9
   PubMedGoogle Scholar
• Day R. O., Miners J. O., Birkett D. J., Whitehead A., Naidoo D., Hayes J., et al. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988; 23: 423–8
   Google Scholar
• Hande K. R., Noone R. M., Stone W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47–56
   PubMed Web of Science ®Google Scholar
• Singer J. Z., Wallace S. L. The allopurinol hypersensitivity syndrome. Unnecessary morbility and mortality. Arthritis Rheum 1986; 29: 82–7
   PubMed Web of Science ®Google Scholar
• Vazquez‐Mellado J., Meoño Morales E., Pacheco‐Tena C., Burgos‐Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981–3
   PubMed Web of Science ®Google Scholar
• Day R. O., Graham G. G., Hicks M., McLachlan A., Stocker S. L., Williams K. M. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623–44
   PubMed Web of Science ®Google Scholar
• Roddy E., Zhang W., Doherty M. Concordance of the management of chronic gout in a UK primary care population with the EULAR gout recommendations. Ann Rheum Dis 2007; 66: 1311–15
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Alonso‐Ruiz A., Calabozo M., Herrero‐Beites A., Garcia‐Erauskin G., Ruiz‐Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545–9
   PubMed Web of Science ®Google Scholar
• Dalbeth N., Kumar S., Stamp L., Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646–50
   PubMed Web of Science ®Google Scholar
• Chawla S. K., Patel H. D., Parrino G. R., Soterakis J., Lopresti P. A., D'Angelo W. A. Allopurinol hepatotoxicity. A case report and review of the literature. Arthritis Rheum 1977; 20: 1546–9
   PubMedGoogle Scholar
• Boston Collaborative Drug Surveillance Program. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. N Engl J Med 2007; 286: 505–7
   Google Scholar
• Halevy S., Ghislain P. D., Mockenhaupt M., Fagot J. P., Bowes Banvick J. N., Sidoroff A., et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2007
   PubMedGoogle Scholar
• Rodevant E., Sletvold O., Kvande K. T. Side effects of allopurinol. Tidsskr Nor Laegeforen 2004; 124: 2618–19
   PubMedGoogle Scholar
• Ichida K., Hosoyamada M., Hisatome I., Enomoto A., Hikita M., Edou H., et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2007; 15: 164–73
   Google Scholar
• Thompson G. R., Duff I. F., Robinson W. D., Galindez H. Long term uricosuric therapy in gout. Arthritis Rheum 1962; 5: 384–96
   PubMed Web of Science ®Google Scholar
• Gutman A. B. Uricosuric drugs, with special reference to probenecid and sulfinpyazone. Adv Pharmacol 1966; 4: 91–142
   PubMedGoogle Scholar
• Schepers G. W. Benzbromarone therapy in hyperuricemia, comparison with allopurinol and probenecid. J Int Med Res 1981; 9: 511–15
   PubMedGoogle Scholar
• Goldfrab E., Smythe C. J. Effects of allopurinol, a xanthine‐oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum 2007; 9: 414–23
   Google Scholar
• Reinders M. K., Van Roon E. N., Houtman P. M., Brouwers J. R., Jansen T. L. Biochemical effectiveness of allopurinol and allopurinol‐probenecid in previously benzbromarone‐treated gout patients. Clin Rheumatol 2007; 26: 1459–65
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Moriwaki Y., Takahashi S., Suda M., Higashino K. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991; 50: 631–3
   PubMedGoogle Scholar
• Jain, Ryan J. R., McMahon F. G., Noveck R. J. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum 1974; 17: 149–57
   PubMedGoogle Scholar
• Sinclair D. S., Fox I. H. The pharmacology of the hypouricemic effect of benzbromarone. J Rheumatol 1975; 2: 437–45
   PubMed Web of Science ®Google Scholar
• Yu T. F. Pharmacokinetic and clinical studies of a new uricosuric agent –benzbromarone. J Rheumatol 1976; 3: 305–12
   PubMedGoogle Scholar
• Hanvivadhanakul P., Akkasilpa S., Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002; 85: S40–7
   PubMedGoogle Scholar
• Ferber B., Bader U., Matzkues F. The action of benzbromarone in relation to age, sex and accompanying diseases. Adv Exp Med Biol 1980; 122A: 287–94
   PubMedGoogle Scholar
• Maly J., Schuck O. The influence of benzbromarone and its combination with hydrochlorothiazide on renal excretion of uric acid and electrolytes. Int J Clin Pharmacol Ther Toxicol 2007; 28: 443–5
   Google Scholar
• Zurcher R. M., Bock H. A., Thiel G. Excellent uricosuric effect of benzbromarone in cyclosporin‐A‐treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9: 548–51
   PubMedGoogle Scholar
• Sorensen L. B., Levinson D. J. Clinical evaluation of benzbromarone. Arthritis Rheum 1976; 19: 183–90
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Calabozo Raluy M., Herrero Beites A., Duruelo J., Ruibal A., Garcia Erauskin G. Utility of urine spot samples for the follow‐up of uricosuric therapy. Rev Esp Reumatol 2007; 28: 57–61
   Google Scholar
• Walter‐Sacks I., de Vries J. X., von Bufnoff A., Pfleilschifster V., Raedsch R. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis: evidence for active benzbromarone metabolites?. Eur J Med Res 1995; 1: 16–20
   PubMedGoogle Scholar
• McDonald M. G., Rettie A. E. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007; 20: 1833–42
   PubMed Web of Science ®Google Scholar
• Jansen T. L., Reinders M. K., Van Roon E. N., Brouwers J. R. Benzbromarone withdrawn form the European market: another case of ‘absence of evidence is evidence of absence’?. Clin Exp Rheumatol 2004; 22: 651–2
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F. New treatment for gout. Joint Bone Spine 2007; 74: 313–15
   PubMedGoogle Scholar
• Perez‐Ruiz F., Nolla J. M. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9: 215–18
   PubMed Web of Science ®Google Scholar
• Loebl W. Y., Scott J. T. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33: 304–7
   PubMed Web of Science ®Google Scholar
• van Lieshout‐Ziudema M. F., Breedveld F. C. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1383–5
   PubMedGoogle Scholar
• Gast L. F. Withdrawal of long‐term antihyperuricemic therapy in patients with tophaceous gout. Clin Rheumatol 1987; 6: 70–3
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Atxotegi J., Hernando I., Calabozo M., Nolla J. M. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long‐term urate‐lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786–90
   PubMed Web of Science ®Google Scholar